Andrology-Open Access

Andrology-Open Access
Open Access

ISSN: 2167-0250

Peng Lee

Peng Lee

Peng Lee, MD, PhD
Executive Editor
Professor, Department of Pathology and Urology
New York University School of Medicine, USA


Dr. Lee is a Professor in the Department of Pathology and Urology at New York University School of Medicine, Director of Molecular Pathology at New York Harbor Healthcare System and co-Director of Genetic Program, Center of Excellence of NYU Urologic Disease. He obtained his MD degree from Beijing Medical University (Peking University, School of Medicine) and PhD from SUNY Downstate Medical Center. Dr. Lee was trained as a postdoctoral fellow with Dr. Robert Roeder at the Rockefeller University. Following his residency in Pathology at NYU Medical Center, he completed a Surgical/Oncologic Pathology fellowship at the University of Texas, M.D Anderson Cancer Center. He is a specialized in Surgical, Oncologic, Genitourinary and Molecular Pathology.

Research Interest

His laboratory consists of basic and translational research program involving the development of endocrine organs and cancer. One of the main focus of his research was on prostate cancer. The clinical treatment of prostate cancer was hindered by:
1) over-treatment of indolent prostate cancer, due to lack of biomarkers to stratify aggressive from indolent cancer.
2) lack of effective treatment for androgen-independent prostate cancer.
To address these issues, the principal research focus of his group was to
1) develop prognostic and predictive biomarkers identifying aggressive prostate cancer.
2) elucidate the molecular mechanism of hormonal (androgen and estrogen) receptors, their cofactors, and target genes in the development of androgen-independent prostate cancer.
A compelling element of his research was to understand how the expression and function of proteins in the stromal AR pathway influences the stromal-epithelial interactions, contributing to tumorigenesis. The long term goal of the lab was to apply these findings to clinically relevant issues; to identify prognostic or predictive biomarkers and to discover novel therapeutic strategies for these cancers.